cts, Inc. (the "Company"), through its indirect
majority-owned subsidiaries, Shandong Taibang Biological Products Co. Ltd. and
Chongqing Dalin Biologic Technologies Co., Ltd, and its equity investment in
Xi'an Huitian Blood Products Co., Ltd., is currently the largest
non-state-owned plasma-based biopharmaceutical company approved by the Chinese
government. The Company is a fully integrated biologic products company with
plasma collection, production and manufacturing, research and development, and
commercial operations. The Company's blood products are irreplaceable during
medical emergencies, and are used for the prevention and treatment of various
diseases. It sells its plasma-based biopharmaceutical products to hospitals
and other healthcare facilities in China.
Safe Harbor Statement
This release may contain certain "forward-looking statements" relating to
the business of China Biologic Products, Inc. and its subsidiary companies.
All statements, other than statements of historical fact included herein are
"forward-looking statements," including statements regarding: the impact of
the Company's forum for strategy and development on the business and
operations of the Company, including the ability of the Company to create
synergies among its subsidiaries; the ability of the Company to achieve its
commercial objectives; the business strategy, plans and objectives of the
Company and its subsidiaries; and any other statements of non-historical
information. These forward-looking statements are often identified by the use
of forward-looking terminology such as "believes," "expects" or similar
expressions, involve known and unknown risks and uncertainties. Although the
Company believes that the expectations reflected in these forward-looking
statements are reasonable, they do involve assumptions, risks and
uncertainties, and these expectations may prove to be incorrect. Investors
should not place undue reliance on
'/>"/>
SOURCE China Biologic Products, Inc. Copyright©2009 PR Newswire. All rights reserved | |
Page: 1 2 3 Related biology technology :1.
NeoStem Featured on CBS2 News; Success of Licensed Stem Cell Treatments Shown for Arthritis and Orthopedic Problems; Procedure to be Used by NeoStem Affiliate in China2.
China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results3.
China-Biotics, Inc. Announces Conference Call to Discuss Fourth Quarter and Full Year 2009 Financial Results4.
China Clean Energy Provides Business Update5.
China Kangtai Cactus Biotech Retains Hawk Associates for Investor Relations Services6.
RainEarth (RNER) Continues to Expand its Marketing Force in China7.
Sinovac Receives Chinas First Influenza A (H1N1) Vaccine Order8.
China-Biotics, Inc. to Join Russell 3000 Index9.
NeoStem Signs Agreement with Shanghai Corporation to Develop A Stem Cell Collection and Treatment Network in Shanghai, Taiwan and Other Targeted China Provinces10.
China Biologic Products Closes the $9.6 Million Private Placement11.
China Biologic Products Enters Into Private Placement Agreements to Raise $9.6 Million